JP2023537600A5 - - Google Patents
Info
- Publication number
- JP2023537600A5 JP2023537600A5 JP2023510340A JP2023510340A JP2023537600A5 JP 2023537600 A5 JP2023537600 A5 JP 2023537600A5 JP 2023510340 A JP2023510340 A JP 2023510340A JP 2023510340 A JP2023510340 A JP 2023510340A JP 2023537600 A5 JP2023537600 A5 JP 2023537600A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- therapeutic agent
- rspa
- targeted therapeutic
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063064555P | 2020-08-12 | 2020-08-12 | |
| US63/064,555 | 2020-08-12 | ||
| US202163168120P | 2021-03-30 | 2021-03-30 | |
| US63/168,120 | 2021-03-30 | ||
| PCT/US2021/045556 WO2022035970A1 (en) | 2020-08-12 | 2021-08-11 | Replication stress pathway agent compositions and methods for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023537600A JP2023537600A (ja) | 2023-09-04 |
| JP2023537600A5 true JP2023537600A5 (https=) | 2024-08-20 |
Family
ID=80247345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023510340A Pending JP2023537600A (ja) | 2020-08-12 | 2021-08-11 | がんを処置するための複製ストレス経路剤組成物および方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11547711B2 (https=) |
| EP (1) | EP4196614A4 (https=) |
| JP (1) | JP2023537600A (https=) |
| KR (1) | KR20230098134A (https=) |
| CN (1) | CN116368243A (https=) |
| AU (1) | AU2021325905A1 (https=) |
| BR (1) | BR112023002453A2 (https=) |
| CA (1) | CA3187760A1 (https=) |
| MX (1) | MX2023001717A (https=) |
| TW (1) | TW202221118A (https=) |
| WO (1) | WO2022035970A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3187760A1 (en) | 2020-08-12 | 2022-02-17 | Boundless Bio, Inc. | Replication stress pathway agent compositions and methods for treating cancer |
| WO2022152899A1 (en) * | 2021-01-18 | 2022-07-21 | Gbg Forschungs Gmbh | Method for predicting the response to cdk4/6 inhibitor therapy in cancer patients |
| BR112023024571A2 (pt) | 2021-05-27 | 2024-02-06 | Boundless Bio Inc | Inibidores de quinase do ponto de verificação 1 (chk1) e usos dos mesmos |
| CN114835640B (zh) * | 2022-05-24 | 2024-02-13 | 中国药科大学 | 成纤维细胞生长因子受体抑制剂、制备方法及应用 |
| WO2024059696A1 (en) * | 2022-09-15 | 2024-03-21 | Recurium Ip Holdings, Llc | Combinations |
| CN116083576B (zh) * | 2022-12-07 | 2024-01-30 | 上海市临床检验中心 | 一种基于CRISPR/Cas12a的KRAS热点基因突变检测系统和方法 |
| WO2025049814A2 (en) * | 2023-09-01 | 2025-03-06 | Boundless Bio, Inc. | Ribonucleotide reductase (rnr) compositions and methods of use |
| WO2025184572A1 (en) * | 2024-03-01 | 2025-09-04 | Zeno Management, Inc. | Wee1 inhibitor combination therapy |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS567007A (en) | 1979-06-29 | 1981-01-24 | Toshiba Corp | Coating film thickness measuring apparatus |
| US12559789B2 (en) * | 2017-01-20 | 2026-02-24 | The Jackson Laboratory | Method of targeting patient-specific oncogenes in extrachromosomal DNA to treat glioblastoma |
| JP7273791B2 (ja) * | 2017-04-10 | 2023-05-15 | シエラ オンコロジー， インコーポレイテッド | 腫瘍成長を阻害するＣＨＫ１（ＳＲＡ７３７）／ＰＡＲＰｉ組み合わせ方法 |
| US11193164B2 (en) * | 2017-05-24 | 2021-12-07 | The Regents Of The University Of California | Methods of diagnosing and treating cancer targeting extrachromosomal DNA |
| CA3065803A1 (en) * | 2017-06-01 | 2018-12-06 | Sierra Oncology, Inc. | Biomarkers and patient selection strategies |
| EP3709981A4 (en) * | 2017-11-15 | 2021-08-11 | The Regents of the University of California | METHOD OF TREATMENT OF EXTRACHROMOSOMAL DNA EXPRESSING CANCER |
| CA3092079A1 (en) * | 2018-02-26 | 2019-08-29 | Sierra Oncology, Inc. | Methods of treatment of cancer comprising chk1 inhibitors |
| US20220010307A1 (en) * | 2018-12-10 | 2022-01-13 | The Regents Of The University Of California | Compositions and methods for modulating transcriptional activity of amplified oncogenes contained on extrachromosomal dna |
| WO2020227255A1 (en) * | 2019-05-06 | 2020-11-12 | The Regents Of The University Of Michigan | Targeted therapy |
| CA3187760A1 (en) * | 2020-08-12 | 2022-02-17 | Boundless Bio, Inc. | Replication stress pathway agent compositions and methods for treating cancer |
| BR112023024571A2 (pt) | 2021-05-27 | 2024-02-06 | Boundless Bio Inc | Inibidores de quinase do ponto de verificação 1 (chk1) e usos dos mesmos |
| WO2023043938A1 (en) | 2021-09-17 | 2023-03-23 | Boundless Bio, Inc. | Sulfamide ribonucleotide reductase (rnr) inhibitors and uses thereof |
| JP2024534420A (ja) | 2021-09-17 | 2024-09-20 | バウンドレス バイオ，インク． | 環状スルホンアミドリボヌクレオチドレダクターゼ（ｒｎｒ）阻害剤およびその使用 |
| US20230272485A1 (en) | 2022-02-16 | 2023-08-31 | Boundless Bio, Inc. | Replication stress pathway agent compositions and methods for treating cancer |
-
2021
- 2021-08-11 CA CA3187760A patent/CA3187760A1/en active Pending
- 2021-08-11 KR KR1020237008613A patent/KR20230098134A/ko not_active Withdrawn
- 2021-08-11 WO PCT/US2021/045556 patent/WO2022035970A1/en not_active Ceased
- 2021-08-11 MX MX2023001717A patent/MX2023001717A/es unknown
- 2021-08-11 BR BR112023002453A patent/BR112023002453A2/pt not_active Application Discontinuation
- 2021-08-11 EP EP21856647.9A patent/EP4196614A4/en active Pending
- 2021-08-11 AU AU2021325905A patent/AU2021325905A1/en not_active Abandoned
- 2021-08-11 CN CN202180069281.4A patent/CN116368243A/zh active Pending
- 2021-08-11 JP JP2023510340A patent/JP2023537600A/ja active Pending
- 2021-08-12 TW TW110129785A patent/TW202221118A/zh unknown
-
2022
- 2022-01-04 US US17/568,434 patent/US11547711B2/en active Active
- 2022-10-21 US US18/048,573 patent/US11642345B2/en active Active
-
2023
- 2023-03-24 US US18/189,453 patent/US12246017B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023537600A5 (https=) | ||
| Aggarwal et al. | SWOG S1400D (NCT02965378), a phase II study of the fibroblast growth factor receptor inhibitor AZD4547 in previously treated patients with fibroblast growth factor pathway–activated stage IV squamous cell lung cancer (Lung-MAP substudy) | |
| Weiss et al. | Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer | |
| JP2024526145A5 (https=) | ||
| Sandhu et al. | Systemic treatment for metastatic colorectal cancer in the era of precision medicine | |
| Finch et al. | P-glycoprotein and its role in drug-drug interactions | |
| Roila et al. | 2016 MASCC and ESMO guideline update for the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients | |
| US20220160714A1 (en) | Methods for treating colorectal cancer | |
| CN102105152B (zh) | 包含cdks抑制剂和抗肿瘤剂的治疗组合 | |
| Goff | Advanced ovarian cancer: what should be the standard of care? | |
| RU2020123665A (ru) | Преимущественные режимы дозирования g1т38 | |
| KR20240074779A (ko) | 약학적 조성물 및 이의 용도 | |
| AU2026201311A1 (en) | Methods and dosing regimens comprising a CDK2 inhibitor and a CDK4 inhibitor for treating cancer | |
| Brown | The treatment of relapsed refractory chronic lymphocytic leukemia | |
| WO2022111714A1 (zh) | 用于治疗pik3ca突变癌症的组合疗法 | |
| IL318887A (en) | Composition and methods of precision cancer treatment | |
| US20250319186A1 (en) | Treatment of canine cancers | |
| TW202329946A (zh) | 用於治療癌症之方法及包含cdk2抑制劑之給藥方案 | |
| Zhao et al. | Narrative review of stereotactic body radiation therapy combined with tyrosine kinase inhibitors for oligometastatic EGFR-mutated non-small cell lung cancer: present and future developments | |
| Gupta et al. | Emerging systemic therapies for the management of penile cancer | |
| JP2013523678A5 (https=) | ||
| CN120713908A (zh) | 帕布昔利布在黏膜恶性黑色素瘤中的应用 | |
| CN119546292A (zh) | 使用lsd1抑制剂治疗恶性周围神经鞘瘤(mpnst)的方法 | |
| Li et al. | Targeting BRCA‐mutant biliary tract cancer: Current evidence and future perspectives | |
| Heng et al. | Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions |